<div><div></div><div><span><p><strong><span>Genprex announced preclinical data showing its Pdx1/MafA gene therapy (PM) reversed hyperglycemia in Type 2 diabetic mouse models.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>Researchers presented at ASGCT that AAV-delivered PM (GPX-002) reversed hyperglycemia in high-fat-diet T2D mice, indicating efficacy.</span></li><li><span>Ex-vivo GSIS and EM showed PM-treated islets had restored insulin secretion, increased mature insulin granules, and improved β-cell function.</span></li><li><span>β-cell–specific (RIP) and global (CMV) PM delivery both improved glucose control and promoted β-cell maturation per transcriptomic analysis.</span></li><li><span>Company says pancreatic delivery via endoscopic retrograde technique is technically translatable to humans, supporting potential long-term glycemic control development.</span></li></ul><p><span>Original SEC Filing: </span>Genprex, Inc. [ GNPX ] - 8-K - May. 14, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

GNPX

SBIO

LABU

ARKG

<p>Genprex announced preclinical data at ASGCT showing that its Pdx1/MafA gene therapy (PM) effectively reversed hyperglycemia in Type 2 diabetic mice. Key findings include restored insulin secretion and improved β-cell function in PM-treated islets. Both β-cell–specific and global PM delivery methods enhanced glucose control and β-cell maturation. The company suggests that the pancreatic delivery technique is feasible for human application, indicating potential for long-term glycemic control.</p>

TradingView

Genprex

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT